Rhodiola rosea
Cognitive · Adaptogen
Tier B+
Bottom line
Read Off Label grades Rhodiola rosea as B+ (7.1/10) based on moderate evidence, med benefit magnitude, and a low-risk safety profile.
Best-studied adaptogen outside of ashwagandha.
Studied, labeled, or reported-use context: 200-600 mg/day standardized extract (3% rosavin, 1% salidroside) — OTC; not individualized guidance.
If you were testing this on yourself
Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.
Can you undo it?
Reverses on stopping
Reversible with no dependence at standardised extract doses.
Can you tell if it worked?
Readable — 1–4 weeks
Subjective fatigue, particularly under a known stressor like shift work or exam periods.
What would fool you Extract standardisation varies widely between products, so a null result may be the product. Fatigue regresses to the mean strongly, and the stressor you started it for usually ends on its own.
What the evidence says
Best-studied adaptogen outside of ashwagandha. Effects generally described as subtle — reduced fatigue and stress tolerance rather than acute stimulation. Most notable in fatigue/burnout states.
Mechanism
Arctic adaptogen; rosavins and salidrosides; modulates HPA axis and monoamine metabolism; reduces cortisol response to stress; mitochondrial support
Studied, labeled, or reported dose & route
200-600 mg/day standardized extract (3% rosavin, 1% salidroside)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Rhodiola rosea's effects?
- Read Off Label rates the evidence for Rhodiola rosea as Moderate and the benefit magnitude as med, producing an overall grade of B+ (7.1/10). Best-studied adaptogen outside of ashwagandha.
- What safety findings are reported for Rhodiola rosea?
- Rhodiola rosea has a low risk profile in the database. Low (generally well-tolerated) Legal status: OTC.
- What doses or routes are reported for Rhodiola rosea?
- 200-600 mg/day standardized extract (3% rosavin, 1% salidroside) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Rhodiola rosea work?
- Arctic adaptogen; rosavins and salidrosides; modulates HPA axis and monoamine metabolism; reduces cortisol response to stress; mitochondrial support
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.